By Counterforce Health Team in Amvuttra (vutrisiran) —

How to Get Amvuttra (Vutrisiran) Covered by Cigna in Pennsylvania: Complete Coverage Criteria Guide

Answer Box: Fast Track to Amvuttra Coverage

Cigna requires prior authorization for Amvuttra (vutrisiran) under Policy IP0478, with approval typically taking 5 business days when all criteria are met. To get coverage in Pennsylvania: (1) Confirm your TTR genetic testing results from a CLIA-certified lab, (2) gather baseline neuropathy documentation from your neurologist, and (3) have your doctor submit the complete PA request through Cigna's provider portal with medical necessity justification. If denied, Pennsylvania's new Independent External Review program has a 53% success rate for overturning insurance denials. Start with Cigna's PA form here.

Table of Contents

  1. Cigna's Coverage Policy Overview
  2. Medical Necessity Requirements
  3. Step Therapy and Exceptions
  4. Required Documentation Checklist
  5. Prior Authorization Process
  6. Appeals Process in Pennsylvania
  7. Common Denial Reasons & Solutions
  8. Financial Assistance Options
  9. FAQ
  10. Sources & Further Reading

Cigna's Coverage Policy Overview

Cigna classifies Amvuttra (vutrisiran) as a non-preferred specialty drug requiring prior authorization for all plan types—HMO, PPO, and Medicare Advantage. The drug is managed through Express Scripts, Cigna's pharmacy benefit manager, under Prior Authorization Policy IP0478.

Coverage applies to:

  • Hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN) in adults
  • ATTR cardiomyopathy (both wild-type and hereditary) in adults

The medication costs approximately $119,351 per quarterly injection (~$477k annually at list price), making prior authorization essential for most patients.

Medical Necessity Requirements

Core Eligibility Criteria

Cigna requires all of the following for approval:

Requirement Documentation Needed Source
Age 18+ years Patient records
Genetic Confirmation TTR gene sequencing showing pathogenic variant from CLIA-certified lab Genetic test report
Symptomatic Disease Clinical exam, electromyography, or nerve conduction studies Neurologist evaluation
Specialist Involvement Prescription by/consultation with neurologist, geneticist, or amyloidosis specialist Provider credentials
No Liver Transplant Medical history documentation Chart notes

Disease-Specific Documentation

For hATTR Polyneuropathy:

  • Neuropathy Impairment Score (NIS) between 5-130
  • Polyneuropathy Disability Score ≤ IIIb (ambulatory)
  • Baseline functional assessments (10-meter walk test, Norfolk QOL-DN)

For ATTR Cardiomyopathy:

  • Echocardiogram or cardiac MRI showing wall thickening
  • NT-proBNP levels
  • NYHA functional class documentation
Clinician Corner: Your medical necessity letter should include the specific TTR variant identified, baseline neuropathy scores, prior therapy trials with outcomes, and citations to FDA labeling supporting the indication.

Step Therapy and Exceptions

Cigna may require step therapy depending on your specific indication:

hATTR Polyneuropathy: Trial of Onpattro (patisiran) may be required first ATTR Cardiomyopathy: Trial of tafamidis (Vyndaqel/Vyndamax) may be required

Step Therapy Override Criteria

You can bypass step therapy by documenting:

  • Previous therapeutic failure of required medication with specific outcomes
  • Documented contraindications (e.g., infusion-related reactions to patisiran)
  • Clinical unsuitability based on your TTR variant or disease stage
Tip: Include specific drug names, doses, duration of trial, and reason for discontinuation in your override request.

Required Documentation Checklist

Patient Information

  • Insurance ID and member number
  • Complete demographic information
  • ICD-10 codes (E85.1 for hATTR-PN, I43.1 for ATTR-CM)

Clinical Documentation

  • TTR genetic test results from CLIA-certified laboratory
  • Baseline neuropathy assessment scores
  • Specialist consultation notes
  • Prior therapy records (if applicable)
  • Contraindication documentation (if requesting step therapy override)

Administrative Requirements

  • Prescriber NPI and specialty credentials
  • Prior authorization form completed
  • Medical necessity letter with guideline citations

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. Pre-Submission (Days 1-2)
    • Gather all required documentation
    • Contact Alnylam Assist for PA support templates
    • Verify patient's current Cigna coverage
  2. Submit Request (Day 3)
    • Use Cigna provider portal (fastest method)
    • Alternative: CoverMyMeds or SureScripts
    • Avoid fax when possible to prevent delays
  3. Track Status (Days 4-5)
    • Monitor via myCigna portal
    • Respond immediately to any information requests
  4. Decision Timeline
    • Standard PA: 5 business days
    • Urgent PA: 72 hours (requires clinical urgency justification)
    • Incomplete submissions: Add 1-7 days for additional information requests
Note: Express Scripts processes most complete submissions within 2 business days according to their standard timelines.

Appeals Process in Pennsylvania

Pennsylvania launched its Independent External Review program in January 2024, giving residents stronger appeal rights than most states.

Internal Appeal (First Level)

  • Deadline: 180 days from denial
  • Timeline: 15 days for standard, 72 hours for urgent
  • Required: Final Adverse Benefit Determination letter

External Review (Second Level)

  • Eligibility: Available after internal appeal completion
  • Deadline: 4 months from final internal denial
  • Timeline: 45 days standard, 72 hours expedited
  • Success Rate: 53% overturn rate in 2024
  • Cost: Free to consumers (insurer pays)

How to File External Review

  1. Visit Pennsylvania Insurance Department website
  2. Complete online form or download paper application
  3. Submit supporting medical documentation
  4. Await Independent Review Organization assignment
Important: Pennsylvania's external review only applies to fully-insured commercial plans, not self-funded employer plans.

Common Denial Reasons & Solutions

Denial Reason Solution Documentation Needed
Missing genetic testing Submit TTR sequencing results CLIA-certified lab report
Inadequate neuropathy documentation Provide baseline scores NIS, mNIS+7, Norfolk QOL-DN
Step therapy not attempted Request override or document trial Prior therapy records with outcomes
Non-specialist prescriber Transfer to specialist Neurologist, geneticist, or amyloidosis specialist
Insufficient medical necessity Strengthen clinical rationale Guidelines, peer-reviewed studies, FDA labeling

Sample Appeal Language

"Patient has confirmed pathogenic TTR variant [specify] with symptomatic polyneuropathy (baseline NIS: [score]). Previous trial of [alternative therapy] resulted in [specific outcome/intolerance]. Amvuttra represents the most appropriate therapy per [cite specific guidelines] given patient's disease stage and prior treatment response."

Financial Assistance Options

Manufacturer Support:

  • Alnylam Assist: Most patients pay $0 out-of-pocket with commercial insurance
  • Copay assistance up to annual maximums
  • Free drug program for uninsured patients meeting income criteria

Additional Resources:

  • Patient Advocate Foundation
  • HealthWell Foundation
  • National Organization for Rare Disorders (NORD)

When dealing with complex prior authorization requirements, Counterforce Health helps patients and clinicians turn insurance denials into targeted, evidence-backed appeals by analyzing denial letters and drafting point-by-point rebuttals aligned to payer policies.

FAQ

How long does Cigna PA take for Amvuttra in Pennsylvania? Standard requests: 5 business days. Urgent requests: 72 hours. Complete submissions typically process faster than incomplete ones.

What if Amvuttra is non-formulary on my Cigna plan? Request a formulary exception with clinical justification demonstrating medical necessity and lack of suitable alternatives.

Can I get expedited review if my condition is worsening? Yes. Both PA and appeals can be expedited with physician certification of clinical urgency.

Does step therapy apply if I failed similar drugs outside Pennsylvania? Yes. Document all prior therapy trials with specific outcomes to support your case.

What happens if Cigna denies my appeal? You can file an external review with Pennsylvania's Insurance Department within 4 months of the final internal denial.

Do I need to see a specialist to get Amvuttra covered? Yes. Cigna requires prescription by or consultation with a neurologist, geneticist, or amyloidosis specialist.

How often do I need reauthorization? Cigna approves Amvuttra for 1 year initially, requiring documentation of clinical response for renewal.

What if I'm on a self-funded employer plan? Pennsylvania's external review doesn't apply to self-funded plans. Check with your employer about internal appeal options.

From our advocates: We've seen the strongest approvals when patients work closely with their neurologist's office to submit comprehensive documentation upfront. One patient's approval was initially delayed due to missing baseline neuropathy scores, but once the complete assessment was submitted, Cigna approved within 3 business days. The key is thoroughness on the first submission.

For complex cases or repeated denials, Counterforce Health specializes in analyzing payer-specific policies and crafting targeted appeals that address the exact criteria insurers use for coverage decisions.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies vary by plan and change frequently. Always verify current requirements with Cigna directly and consult your healthcare provider for medical decisions. For assistance with Pennsylvania insurance issues, contact the Pennsylvania Insurance Department at 1-877-881-6388.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.